AzTrials
AzTrials

Diabetic Kidney Disease (DKD)Phase 2ANCHOR-POCNCT07271186

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

A Phase 2 study testing ALN-ANG3 and Evinacumab in people with Diabetic Kidney Disease (DKD), run by Regeneron Pharmaceuticals at 59 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Diabetic Kidney Disease (DKD)
What is being tested?
ALN-ANG3 and Evinacumab
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
195 participants
Where
59 sitesUnited States
Study dates
9 Jan 2026to 13 Oct 2028
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Medical history of type 2 diabetes and receiving medical therapy or lifestyle interventions for glucose management
  • Hemoglobin A1C (HbA1c) of 6.5 to 10% at screening
  • eGFR 30 to 90 mL/min/1.73 m^2 using 2021 Chronic Kidney Disease-Epidemiology Collaboration-Estimated Glomerular Filtration Rate using Creatinine and Cystatin C (CKD-EPI eGFRcr-cys) equation at screening
  • Albuminuria: Urine Albumin to Creatinine Ratio (UACR) of 500 to 5000 mg/g at screening

Who cannot join

  • Known medical history or clinical evidence indicative of non-diabetic renal disease
  • Renal disease that required treatment with systemic immunosuppressive therapy (prior or current), or a history of end-stage kidney disease requiring treatment with chronic dialysis or kidney transplantation
  • Medically unstable as assessed by the investigator or hospitalization (ie, >24 hours) within 30 days of the screening visit
  • NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply

Trial locations and contacts

59 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Clinical Trials Administrator contact

844-734-6643

clinicaltrials@regeneron.com

59 sites in 1 country

United States59 sites, 57 recruiting

  • University of Michigan

    Ann Arbor, Michigan, 48109

    Recruiting

  • Arlington Nephrology, PLLC.

    Arlington, Texas, 76015

    Recruiting

  • Northeast Clinical Research Center

    Bethlehem, Pennsylvania, 18017

    Recruiting

  • Velocity Clinical Research

    Binghamton, New York, 13905

    Recruiting

  • Southeast Renal Research Institute

    Chattanooga, Tennessee, 37404

    Withdrawn

  • Research by Design, LLC - Internal Medicine

    Chicago, Illinois, 60643

    Recruiting

  • Elixia MNA

    City of Saint Peters, Missouri, 63376

    Recruiting

  • M3 Wake Research Dallas - Internal Medicine

    Dallas, Texas, 75224

    Recruiting

  • Revival Research Institute, LLC

    Dallas, Texas, 75231

    Recruiting

  • Epic Medical Research LLC

    DeSoto, Texas, 75115

    Recruiting

  • D&H Doral Research Center

    Doral, Florida, 33122

    Recruiting

  • El Paso Kidney Specialists-Davita Clinical Research

    El Paso, Texas, 79902

    Recruiting

  • Eastern Nephrology Associates - Greenville West

    Greenville, North Carolina, 27834

    Recruiting

  • AGA Clinical Trials

    Hialeah, Florida, 33012

    Recruiting

  • Convenient Medical Center

    Hialeah, Florida, 33013

    Recruiting

  • Elixia Hollywood

    Hollywood, Florida, 33024

    Recruiting

  • Juno Research, LLC

    Houston, Texas, 77040

    Recruiting

  • Prolato Research LLC

    Houston, Texas, 77054

    Recruiting

  • Clinical Trial Network, LLC

    Houston, Texas, 77074

    Recruiting

  • AME Clinical Research

    Huntington Beach, California, 92647

    Recruiting

  • Apogee Clinical Research, LLC

    Huntsville, Alabama, 35801

    Recruiting

  • Clinical Research Consultants, LLC

    Kansas City, Missouri, 64111

    Recruiting

  • Gulf Coast Clinical Research

    Katy, Texas, 77450

    Recruiting

  • R & H Clinical Research, Inc.

    Katy, Texas, 77450

    Recruiting

  • DaVita Clinical Research

    Las Vegas, Nevada, 89107

    Recruiting

  • Applied Research Center of Arkansas

    Little Rock, Arkansas, 72205

    Recruiting

  • D&H Pompano Research Center

    Margate, Florida, 33063

    Recruiting

  • Sunbeam Clinical Research

    McKinney, Texas, 75069

    Recruiting

  • LCC Medical Research Institute

    Miami, Florida, 33126

    Recruiting

  • D&H National Research Centers, Inc

    Miami, Florida, 33155

    Recruiting

  • Regenerate Primary Medical Research, LLC

    Miami, Florida, 33155

    Recruiting

  • Ocean Blue Medical Research Center - Internal Medicine

    Miami Springs, Florida, 33166

    Recruiting

  • Innovia Research Center

    Miramar, Florida, 33027

    Recruiting

  • IMA Clinical Research

    Monroe, Louisiana, 71201

    Recruiting

  • Eastern Nephrology Associates - New Bern

    New Bern, North Carolina, 28562

    Recruiting

  • Yale University

    New Haven, Connecticut, 06510

    Recruiting

  • Amicis Research Center

    Northridge, California, 91325

    Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

    Recruiting

  • Central Florida Kidney Specialists Oakwater

    Orlando, Florida, 32806

    Recruiting

  • FOMAT - Vista del Mar Medical Group

    Oxnard, California, 93036

    Recruiting

  • Bolanos Clinical Research

    Pembroke Pines, Florida, 33026

    Recruiting

  • Elixia Michigan Kidney Consultants

    Pontiac, Michigan, 48341

    Recruiting

  • Progressive Medical Research

    Port Orange, Florida, 32127

    Recruiting

  • CDC Research Institute

    Port Saint Lucie, Florida, 34952

    Recruiting

  • Central Coast Nephrology

    Salinas, California, 93901

    Withdrawn

  • Clinical Advancement Center

    San Antonio, Texas, 78212

    Recruiting

  • University of Texas Health - San Antonio

    San Antonio, Texas, 78229

    Recruiting

  • North America Research Institute

    San Dimas, California, 91773

    Recruiting

  • Amicis Research Center

    Santa Clarita, California, 91355

    Recruiting

  • Privia Medical Group of Georgia, LLC

    Savannah, Georgia, 31406

    Recruiting

  • Providence Medical Research Center

    Spokane, Washington, 99204

    Recruiting

  • D&H Tamarac Research Center

    Tamarac, Florida, 33321

    Recruiting

  • Valiance Clinical Research

    Tarzana, California, 91356

    Recruiting

  • CHEAR Center LLC

    The Bronx, New York, 10455

    Recruiting

  • Amicis Research Center

    Valencia, California, 91355

    Recruiting

  • National Institute of Clinical Research, Inc.

    Victorville, California, 92392

    Recruiting

  • Suburban Research Associates

    West Chester, Pennsylvania, 19380

    Recruiting

  • Metabolic Research Institute

    West Palm Beach, Florida, 33401

    Recruiting

  • Brookview Hills Research Associates, LLC

    Winston-Salem, North Carolina, 27103

    Recruiting

Other trials in United States

About this study

Official title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ALN-ANG3 in Participants With Diabetic Kidney Disease

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease.

The aim of the study is to see how safe and effective the study drugs are.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
Being tested
ALN-ANG3, Evinacumab, Placebo
Keywords
Diabetic Nephropathy, Chronic Kidney Disease (CKD), Type 2 Diabetes, Lipid Management, Renal Impairment, Gene Silencing, siRNA, small-interfering RNA
Medical subject headings
Diabetic Nephropathies, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2, Renal Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ALN-ANG3Drug

    Administered per the protocol

  • EvinacumabDrug

    Also called Evkeeza®, R1500

    No longer being administered

  • PlaceboDrug

    Administered per the protocol

Study groups in NCT07271186
Study groupRoleWhat they receive
ALN-ANG3 + evinacumabExperimentalThis arm has been closed
Receives: Drug: ALN-ANG3; Drug: Evinacumab
ALN-ANG3ExperimentalNot described
Receives: Drug: ALN-ANG3
PlaceboPlacebo comparatorNot described
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percent Change in Urine Albumin to Creatinine Ratio (UACR)

    Measured: Baseline to Week 24

Secondary outcomes (13)

  1. Change in Estimated Glomerular Filtration Rate (eGFR)

    Measured: Baseline to Week 24

  2. Change in Total Cholesterol

    Measured: Baseline to Week 24

  3. Change in Low-Density Lipoprotein-Cholesterol (LDL-C)

    Measured: Baseline to Week 24

  4. Change in High-Density Lipoprotein-Cholesterol (HDL-C)

    Measured: Baseline to Week 24

  5. Change in Non-High-Density Lipoprotein-Cholesterol (non-HDL-C)

    Measured: Baseline to Week 24

  6. Change in Triglycerides

    Measured: Baseline to Week 24

  7. Change in Apolipoprotein B (ApoB)

    Measured: Baseline to Week 24

  8. Concentration of Combined ALN-ANG3 and Metabolite(s)

    Measured: Up to Week 24

  9. Change in Concentration of Angiopoietin-Like Protein-3 (ANGPTL-3)

    Measured: Baseline to Week 24

  10. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Measured: Up to Week 48

  11. Severity of TEAEs

    Measured: Up to Week 48

  12. Occurence of Anti-Drug Antibodies (ADAs) to ALN-ANG3

    Measured: Through Week 24

  13. Magnitude of ADAs to ALN-ANG3

    Measured: Through Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Dec 2025
  2. Study start9 Jan 2026
  3. Primary completion13 Oct 2028 (estimated)
  4. Study completion13 Oct 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
195 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07271186
Sponsor's protocol ID
ALN-ANG3-CKD-2502
Other IDs
2026-527519-41-00
Acronym
ANCHOR-POC
Status last verified
Oct 2026
First submitted
21 Nov 2025
Last updated
27 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing ALN-ANG3 and Evinacumab in people with Diabetic Kidney Disease (DKD), run by Regeneron Pharmaceuticals at 59 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 59 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Clinical Trials Administrator (844-734-6643, clinicaltrials@regeneron.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percent Change in Urine Albumin to Creatinine Ratio (UACR) (time frame: Baseline to Week 24). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07271186.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in